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This review presents data on commercial and experimen-
tal virus-like particle (VLP) vaccines, including descrip-
tion of VLP vaccines against influenza. Virus-like particles 
are multimeric, sometimes multiprotein nanostructures 
assembled from viral structural proteins and are devoid 
of any genetic material. VLPs present repetitive high-
density displays of viral surface proteins. Importantly, 
they contain functional viral proteins responsible for cell 
penetration by the virus, ensuring efficient cell entry and 
thus tissue-specific targeting, determined by the origin 
of the virus. The foremost application of VLPs is in vac-
cinology, where they provide delivery systems that com-
bine good safety profiles with strong immunogenicity 
and constitute a safe alternative to inactivated infectious 
viruses. These stable and versatile nanoparticles display 
excellent adjuvant properties capable of inducing in-
nate and cognate immune responses. They present both, 
high-density B-cell epitopes, for antibody production 
and intracellular T- cell epitopes, thus inducing, respec-
tively, potent humoral and cellular immune responses. 
Uptake of VLPs by antigen-presenting cells leads to ef-
ficient immune responses resulting in control of patho-
genic microorganisms.
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VIRUS-LIKE PARTICLES
Virus-like particles (VLP) are multimeric, sometimes 
multiprotein nanostructures that are assembled from 
viral structural proteins and are devoid of  any genetic 
material. These naturally occurring bionanomaterials of-
ten emulate the conformation of  authentic viruses. VLPs 
contain repetitive high-density displays of  viral surface 
proteins and as such are a highly adaptable platform for 
various applications. Importantly, they contain functional 
viral proteins responsible for cell penetration by the vi-
rus, which ensures efficient cell entry.
The foremost application of  VLPs is in vaccinol-
ogy, whereby they provide delivery systems that com-
bine good safety profiles with strong immunogenicity. 
Traditionally, vaccines against viral diseases have been 
prepared from attenuated or inactivated infectious viral 
strains. VLPs, devoid of  the viral genome but able to 
penetrate cells and tissues, are a much safer alternative. 
Moreover, they provide a polyvalent structure that can 
accommodate multiple copies of  antigens and, in addi-
tion, are able to stimulate immune cells. Finally, they en-
sure tissue-specific targeting, determined by the origin of  
the virus.
These stable and versatile nanoparticles display excel-
lent adjuvant properties capable of  inducing innate and 
cognate immune responses. They present both, high-
density B-cell epitopes for antibody production and in-
tracellular T-cell epitopes, thus inducing respectively, 
potent humoral and cellular immune responses (Beyer et 
al., 2001; Wang & Roden, 2013). Indeed, VLPs show po-
tent adjuvant activity enhancing the immunogenicity of  
weakly immunogenic peptides and proteins. They direct 
antigenic peptides/proteins to immature dendritic cells 
(DC), activating DC maturation. Mature DCs are the key 
antigen presenting or antigen-presentig step (APC) that 
efficiently mediate antigen transport to lymphoid tissues 
for the initiation of  T cell responses and induction of  
cell-mediated immunity (Zinkernagel, 2014). Uptake of  
the VLPs by APC leads to efficient immune responses 
and results in the control of  pathogenic microorganisms.
Like parental viruses, VLPs can be either non-envel-
oped or enveloped, and spherical or filamentous (Fig. 1). 
Analysis of  the published data performed by Zeltins 
(2013) revealed that at least 110 VLPs have been con-
structed from viruses belonging to 35 different families. 
They form spontaneously during the viral cycle or in 
heterologous systems upon expression of  one or several 
viral structural proteins. Depending on the complexity 
of  the VLPs, they can be produced from appropriate 
recombinant vectors in either prokaryotic or eukaryotic 
expression systems, or assembled under cell-free condi-
tions. Furthermore, they can be formed from proteins 
derived from a single virus, in order to obtain immunity 
to this virus, or alternatively, on a platform derived from 
a single virus to present proteins/peptides derived from 
other microorganism or any cell/tissue (chimeric VLPs).
The yield of VLPs production is rather high and even 
in eukaryotic systems can approach the expression effi-
ciency comparable to that observed for bacterial expres-
sion systems. Due to their high molecular weight, VLPs 
are purified from extracts of expressing cells by sucrose 
density centrifugation, usually followed by an additional 
step to remove cellular components loosely attached to 
them.
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VLP VACCINES
When VLP is used as a platform for the presentation 
of  foreign epitopes, in majority of  cases this is achieved 
through modification of  the VLP gene sequence, so that 
fusions of  VLP components with a foreign epitope are 
assembled into VLPs during expression. When large pro-
tein domains are needed as an antigen, they might be 
more difficult to display on VLPs, as such insertions may 
be incompatible with the VLP assembly. In that case, a 
chemical conjugation can be a solution.
Some VLP vaccines have been licensed and commer-
cialized, others have entered clinical development, while 
many are in the proof-of-hypothesis stage. Prophylactic 
human vaccines, based on VLPs that have been regis-
tered and are in use protect against hepatitis B virus 
(HBV) and human papilloma virus (HPV) infections.
Hepatitis B vaccine. Hepatitis B virus infection is one 
of  the most common human diseases. Each year over 
one million people die from HBV-related chronic liver 
diseases. Hepatitis B vaccine became the first recombi-
nant protein-based vaccine for humans, approved by the 
Figure 1. Different virus-like particles. 
(A) Diagram of assembly of polyoma VLP from the L1 capsid protein. Five L1 monomers form spontaneously one pentameric L1 cap-
somer, 72 of such capsomers self-assemble into a VLP. From German Cancer Research site http://www.dkfz.de. (B) The hamster polyoma-
virus (HaPyV) VLPs formed from major capsid protein VP1. Electron microscopy (EM) reproduced from the site of the Vilnius University 
http://www.ibt.lt/en/laboratories/egil_en. (C) Cryo-electron microscopy reconstruction of the small BKV (polyoma family) VLP formed in a 
calcium-dependent manner from the P1 protein of a human BK virus. Bar, 10nm. After Nilsson et al. (2005). (D) Eight of respiratory syncy-
tial virus (RSV) trimeric fusion proteins expressed in a baculovirus system form VLPs, visualized by EM. After Novavax. (E) Structure of the 
hepatitis E virus-like particle (HEV VLP). Left panel — atomic structure of HEV VLP. The 3 domains, S, P1, and P2 are colored blue, yellow, 
and red, respectively. Right panel — cryo-EM reconstruction at 14Å resolution. After Guu et al. (2009). (F) Bluetongue virus-like VLPs, re-
quiring the simultaneous expression of four distinct proteins in varying amounts. VLPs are produced in Nicotiana benthamiana using the 
cowpea mosaic virus-based HyperTrans (CPMV-HT) and associated pEAQ plant transient expression vector system. After Thuenemann et 
al. (2013). (G) Ebola VLP visualized by EM. Reproduced from somapps.med.upenn.edu site. (H) Influenza VLPs. Left panel — EM of nega-
tively stained A/Anhui/1/2013 (H7N9) VLP, assembled from HA and NA proteins expressed from separate baculovirus vectors in insect 
cells. After Smith et al. (2013). Right panel — influenza VLPs were produced in a baculovirus system with the sequences of the genes for 
HA, NA, and M1 of the 1918 pandemic virus. After Perrone et al. (2009).
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Federal Drug Administration (USA) in 1986. It is based 
on a recombinant HBV surface antigen (HBsAg), which 
upon production in yeast or mammalian cells forms 22- 
nm spherical VLPs that are adsorbed on an aluminum 
hydroxide gel (Greiner et al., 2012). These particles are 
composed of  host cell-derived lipids (30–50%) and about 
70 copies of  the S protein (226 amino acid residues, 
~25 kDa) and are stabilized by intra- and intermolecular 
disulfide bonds. Contrary to mammalian-derived HBsAg 
particles, yeast-derived particles contain unglycosylated S 
protein. Highly hydrophobic S protein in HBsAg VLPs 
is in tight association with lipids that have been shown 
to be responsible for the antigenic properties of  HB-
sAg particles, stabilizing their structure and protein con-
formation. Thus, these VLPs exhibit a lipoprotein-like 
structure with an ordered and rather rigid lipid interface 
and a more hydrophobic and fluid inner core. Protein 
molecules included in each particle display a protruding 
part and another one deeply inserted into the lipid core 
(Greiner et al., 2010). Loss of  protein protrusions due 
to particle heating at 60ºC modifies the organization of  
both the lipid core and lipid membrane surface, followed 
by a loss of  HBsAg antigenicity (Greiner et al., 2014).
A course of  2–3 vaccine injections is given intramus-
cularly, the second injection at least one month after the 
first one and the third injection being administered up 
to six months after the first one. The induced anti-HBV 
antibodies and immune system memory provide immuni-
ty to hepatitis B infection. The common brands available 
are Recombivax HB (Merck), Engerix-B (GlaxoSmith-
Kline Biologicals), Elovac B (Human Biologicals Insti-
tute), Genevac B (Serum Institute), Shanvac B (Shanta 
Biotechnics in India), etc. Engerix-B contains purified 
surface antigen (HBsAg) of  HBV expressed in yeast, and 
although it is not glycosylated, it is immunogenically and 
physically similar to the antigen isolated from the plasma 
of  chronic carriers (Drug master file at http://www.fda.
gov/BiologicsBloodVaccines/Vaccines/ApprovedProd-
ucts/ucm110102.htm). Protection lasts for at least 25 
years in cases of  adequate initial response to vaccination, 
but some guidelines now recommend a single booster 
after 5 years. The hepatitis B vaccine was found to be 
generally safe although the Engerix B vaccine appeared 
to triple the risk of  CNS inflammatory demyelination 
in infant boys (Mikaeloff  et al., 2009). A possible culprit 
is thiomersal, a mercury-containing vaccine preservative 
that is currently being phased out in many countries.
HPV vaccine. About 30 to 40 types of  HPV can be 
transmitted through sexual contact, via the anogenital re-
gion. Persistent infection with high-risk HPV types — 
different from the ones that cause skin warts — may pro-
gress to precancerous lesions and invasive cancer. Cervi-
cal cancer is an important public health problem world-
wide, especially in developing countries. HPV vaccines 
are virus-like particles assembled from 72 pentamers of  
HPV major capsid protein — L1. Two kinds of  prophy-
lactic HPV vaccines exist: a bivalent vaccine (Cervarix) 
that offers protection against HPV serotypes 16 and 
18, and a quadrivalent vaccine (Gardasil) that protects 
against infection with serotypes 6, 11, 16, and 18. The 
GlaxoSmithKline-manufactured Cervarix contains 20 µg 
each of  HPV16 L1, and HPV18 L1 proteins expressed 
in a baculovirus system, while the Merck-manufactured 
Gardasil contains 20 µg of  HPV6 L1, 40 µg of  HPV11 
L1, 40 µg of  HPV16 L1, and 20 µg of  HPV18 L1 pro-
teins; these proteins are expressed in yeast, purified, and 
combined to make the vaccine. These vaccines contain 
in addition adjuvants such as alumina (aluminum hydrox-
ide) and AS04 with monophosphoryl lipid A (MPL) in 
Cervarix, and amorphous aluminum hydroxyphosphate 
sulfate in Gardasil. Such vaccines are highly efficacious 
if  given before exposure to HPV, i.e. to adolescent girls 
between 9 and 13 years of  age in a three-dose schedule. 
The current duration of  protection is 8.4 years with the 
bivalent vaccine and 5 years with the quadrivalent vac-
cine. A development of  a nine-valent prophylactic HPV 
vaccine (HPV6/11/16/18/31/33/45/52/58) is currently 
being undertaken. Research is also directed towards the 
development of  a prophylactic L2 vaccine and therapeu-
tic vaccines (active after infection).
EXPERIMENTAL VLP VACCINES
A large number of  VLP-based vaccine candidates is 
undergoing a clinical evaluation. The site clinicaltrials.gov 
lists 88 studies for VLP vaccines, created predominantly 
against viral infections. Among them, there are 29 com-
pleted trials for HPV L1 VLP vaccines, three trials for 
Norwalk (norovirus) VLP vaccines, one for Chikungunya 
VLP vaccine, etc. An interesting case is a completed trial 
for a therapeutic anti-HIV vaccination with p17/p24:Ty- 
VLP, which investigates the immunity of  VLP made of  
yeast Ty protein and decorated with HIV p24 protein. 
However, this vaccine, although it elicited antibodies 
against p24 (and Ty) was not able to slow the progres-
sion of  HIV-1 disease (Lindenburg et al., 2002). There is 
also a trial listed on a non-viral vaccine, against essential 
hypertension, which consists of  angiotensin II (Ang II), 
a naturally occurring octapeptide, coupled to the sur-
face of  Qβ bacteriophage VLP. This vaccine decreased 
the blood pressure of  Ang II-induced hypertensive mice 
(Chen et al., 2013).
Some clinical trials concern investigation of  anti-
cancer VLP vaccines. Melan-A VLP and CYT004-
MelQbG10 vaccines for melanoma patients consist of  a 
melanocyte differentiation antigen Melan A (also called 
MART-1) encapsulated in Qβ VLP together with short 
immunostimulatory oligonucleotides (CpGs) or other ad-
juvants. Upon administration, this vaccine may activate 
the immune system to exert a specific cytotoxic T lym-
phocyte (CTL) response against cancer cells expressing 
Melan A antigen that is upregulated in most melanomas. 
Indeed, Melan A vaccination resulted in an increase of  
T-cells at the injection site (Goldinger et al., 2010).
INFLUENZA VLPS VACCINES
Commercial influenza vaccines are either conventional 
vaccines made of  killed virus or “split” or subunit vac-
cines that require an influenza virus that grows well 
enough in eggs or cultured mammalian cells to produce 
sufficient amounts of  the essential vaccine antigen, he-
magglutinin (HA). Split vaccines are produced in the same 
way as whole virus vaccines, but virus particles are disrupt-
ed using detergents. Subunit vaccines consist of  purified 
HA and NA proteins, with the other viral components 
removed. Growing and preparation of  such vaccines is 
rather long and expensive. Development of  recombinant 
HA-based vaccines might help to overcome these limita-
tions, but some doubts persist concerning the effective-
ness of  vaccines based only on HA. Presumably they are 
not able to elicit cell-mediated immunity and thus to im-
munize against different influenza strains. Influenza VLPs 
composed of  more than one influenza protein could con-
ceivably provide a solution to these shortcomings. For this 
purpose, corresponding influenza genes are usually cloned 
into the baculovirus vectors in order to produce multipro-
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tein influenza VLPs in insect cells. Assembled VLPs are 
then secreted as enveloped, pleomorphic particles (Fig. 1) 
resembling influenza virions.
Already in 2005 it has been shown that VLPs built of  
the HA, NA, and M1 proteins of  H9N2 influenza virus 
induced a protective immune responses in mice (Pushko 
et al., 2005). Somewhat later similar results were obtained 
for H5N1 VLPs in mice and H1N1 VLPs in humans 
(Bright et al., 2008; Lopez-Macias et al., 2011). These vac-
cines were shown to display conformation-dependent 
antigenic epitopes associated with HA oligomers and in-
duced robust anti-HA and anti-NA antibody responses 
in clinical studies.
The site clinicaltrials.gov lists human trials with influenza 
VLPs vaccines, namely for: trivalent seasonal VLP vac-
cine (Novavax), H5N1 VLP (pandemic influenza), H1N1 
2009 VLP vaccine and seasonal VLP vaccine (Novavax 
trivalent and quadrivalent vaccines). Interesting cases are 
represented by three plant-made vaccines — H5 VLP 
vaccine (alum-adjuvanted plant-made VLPs containing 
the HA protein of  H5N1 influenza, Landry et al., 2010), 
H1 VLP vaccine (single non-adjuvanted dose of  the H1 
VLP influenza vaccine), and H5-VLP + GLA-AF vac-
cine. In the latter case the vaccine consists of  recom-
binant H5 and N1 proteins produced in a plant-based 
expression system and assembled into virus-like parti-
cles together with the adjuvant glucopyranosyl Lipid A 
(GLA-AF) or with the alum adjuvant. None of  the in-
fluenza VLP vaccines has been approved so far.
It appears that in these trials, apart from investigat-
ing the immune response, emphasis is placed on the use 
of  appropriate adjuvants in order to obtain a more pro-
nounced response of  the immune system. This is sur-
prising since it has been demonstrated that VLPs display 
excellent adjuvant properties, capable of  inducing innate 
and cognate immune responses. However, it is plausible 
that since polymorphous, asymmetric influenza VLPs 
do not contain repetitive high-density viral surface pro-
teins like the homogenous symmetrical VLPs, they are 
not capable of  presenting epitopes in a way required for 
eliciting a strong immune response. Indeed, it has been 
shown that when the cytotoxic T lymphocyte epitope, a 
peptide derived from influenza A virus, was presented 
on a symmetrical platform formed of  SV40 VLP, in-
fluenza-specific CTLs were induced, and heterosubtypic 
protection against influenza A viruses was achieved with-
out the need of  adjuvants (Kawano et al., 2014).
ADENOVIRAL DODECAHEDRON AS VACCINE 
PLATFORM
Vaccines against human papillomavirus and hepatitis 
B are VLP vaccines constructed to protect against their 
virus of  origin. However, VLPs can also be used to pre-
sent foreign epitopes to the immune system (chimeric 
VLPs). When constructing a novel influenza vaccine, 
we used the VLP platform built from a protein derived 
from the adenovirus (Ad) for carrying the epitopes of  
influenza virus, with the goal of  establishing immunity 
against influenza and not against Ad infection (Szurgot 
et al., 2013).
Adenoviral dodecahedra are non-enveloped symmetri-
cal VLPs built from 12 pentons, which are non-covalent 
complexes composed of  pentameric penton bases and 
trimeric fiber proteins, both proteins being responsible 
for intracellular penetration of  the virus (Fig. 2). These 
VLPs, smaller than the virus of  origin, are generated 
during the life cycle of  certain adenovirus serotypes, in-
cluding human adenovirus serotype 3 (Ad3), where they 
participate in spread of  progeny virus through loosen-
ing of  tight junctions (Fender et al., 2005; 2012; Lu et 
al., 2013). These so called dodecahedra-fibre (DFs) of  
4.8 MDa and diameter of  about 50 nm can also be pro-
duced upon expression of  Ad3 pentons in the baculovi-
rus system. Formation of  these particles is solely due to 
penton base interactions, as attested, upon expression of  
the penton base protein alone, by the formation of  do-
decahedra devoid of  fibers, with molecular weight of  3.6 
MDa and diameter of  28 nm (called dodecahedra-base 
DB, hereafter referred to as Dd, Fig. 2A). Stability of  
the dodecameric structure does not depend on disulfide 
bridges or cations as in other VLPs (Simon et al., 2014). 
Instead, the major mechanism of  stability lies in inter-
locking of  the 60 N-terminal domains derived from 12 
pentameric penton bases, which results in formation of  
a strong net stabilizing the VLP (Szolajska et al., 2012). 
Dds retain integrity under different physicochemical con-
ditions, which enables their convenient storage as well 
as attachment of  therapeutic agents (Zochowska et al., 
2009).
Dds efficiently penetrate cellular plasma membrane and 
access the cytoplasm, whereupon up to 300 000 particles 
can be observed in one cell in vitro (Garcel et al., 2006). 
This extraordinary internalization capacity makes Dd a 
very attractive delivery tool. Ad3 Dd inventors first pro-
posed the use of  adenoviral dodecahedron for human 
gene therapy as an alternative to whole adenovirus (Fend-
er et al., 1997). Later, both DF and Dd have been used 
as vectors for direct intracellular delivery of  anti-cancer 
agents covalently attached to the vector surface or as facil-
itators of  drug delivery to tumors (Fender et al., 2003; Zo-
chowska et al., 2009; Wang et al., 2011a; Wang et al., 2011b; 
Beyer et al., 2011; Wang et al., 2013; Zochowska et al., 
2014). Intracellular delivery, important in both therapeutic 
and fundamental applications, faces two major challenges: 
efficient cellular uptake and avoiding endosomal sequestra-
tion. It appears that adenoviral Dd displays properties of  
the virus of  its origin that ensures a remarkably efficient 
penetration without endosomal sequestration.
Another possible application of  dodecahedron, typical 
for VLPs, is in vaccine construction as a delivery plat-
form for foreign antigens. Importantly, VLP size sug-
gests that it will be able to target not only dendritic cells 
at the injection site, but also lymph node-resident DC. 
In order to attach proteins of  interest to Dd, initially a 
system was designed that takes advantage of  the interac-
tion of  proline-rich PPVY motifs in the N-terminus of  
penton base (VLP building block) with cellular structural 
domains called WW. The WW modules served as adap-
tors, on average enabling delivery of  more than ten mil-
lion active protein molecules per cell (Garcel et al., 2006). 
This attachment mode was also used for delivery of  a 
model antigen, ovalbumin (OVA), with DF. Immuniza-
tion with WW-OVA/DF induced integrated humoral and 
antigen specific T-cell responses which resulted in effec-
tive prophylactic and therapeutic protection against the 
highly aggressive B16-OVA melanoma in mice (Villegas-
Mendez et al., 2010). Thus, antigen delivery by a dodeca-
hedric vector seems to be a promising novel strategy for 
development of  oncological vaccines.
EXPERIMENTAL INFLUENZA VACCINE CONSTRUCTED 
ON AN ADENOVIRAL DODECAHEDRON PLATFORM
We exploit the features of  the adenoviral dodecahe-
dron for engineering a multivalent vaccination platform 
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carrying two different influenza antigens - matrix protein 
M1 and hemagglutinin. This kind of  vaccine should be 
able to induce both humoral and cell-mediated immunity, 
possibly providing long lasting protection against differ-
ent strains of  influenza virus. As described earlier, viral 
surface protein, hemagglutinin (HA, 568 residues), is the 
key antigen of  influenza virus able to induce antibodies 
neutralizing viral penetration (Knossow & Skehel, 2006). 
However, due to the high mutation rate, traditional vac-
cines mainly based on HA confer protection only against 
the immunizing and closely related virus strains and are 
ineffective against strains with serologically distinct HA. 
In contrast, an internal matrix protein M1 (252 aa resi-
dues), the most conserved influenza virus protein (Ito et 
al., 1991), is capable of  stimulating cellular immunity of  
the infected hosts, eliciting cytotoxic T lymphocytes ac-
tivity in mice and generating specific CD8+T response 
in humans (Webster & Hinshaw, 1977; Garigliany et al., 
2010; Lee et al., 2008). Thus, the use of  M1 as an anti-
gen could increase effectiveness of  the vaccine, in addi-
tion to protection afforded by anti-HA.
At first, we constructed a vaccine composed of  Dd 
as a platform for delivery and presentation, decorated 
with multiple copies of  the complete matrix protein M1 
(Naskalska et al., 2009) using yeast-derived WW domains 
as adaptors. The M1 protein was expressed in bacteria 
with a GST-tag at the N-terminus and with a WW linker 
at the C-terminus. N-lauroylsarcosine-solubilized GST-
M1WW protein was purified on Glutathione-Sepharose 
and subsequently incubated with Dd, which allowed 
formation of  Dd-M1WW VLP decorated with approxi-
mately 10 copies of  the M1 protein. Successful internali-
Figure 2. Adenoviral dodecahedron. 
(A) Adenoviral dodecahedra. Left panels depict schematically the assembly of Dd (dodecahedron base, DB) and DF from adenovirus 
penton bases or pentons, respectively. Middle panels show cryo-electron microscopy of Dd and DF (from Fender et al., 1997), while 
right panels show Dd and DF structure at 9Å resolution (from Fuschiotti et al., 2006). (B) Diagram of Dd formation bearing multiple M1 
epitopes. (C) Schematic view of vaccine interaction with dendritic cells resulting in epitope presentation to T lymphocytes and inducing 
secretion of gamma interferon, a marker of cellular immunity.
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zation of  Dd-M1WW into myeloid dendritic cells (MDC, 
the most important antigen presenting cells, APC) was 
demonstrated by flow cytometry, with no internaliza-
tion of  GST-M1WW alone. Functional analyses demon-
strated that the Dd-M1WW vaccine activated MDC and 
efficiently triggered specific cell-mediated responses. In-
deed, formation of  motile cytoplasmic veils (Fig. 3) and 
upregulation of  specific activation markers, CD40 and 
CD80, demonstrated maturation and activation of  DC. 
Moreover, Dd carrying M1WW was efficiently presented 
by MDC to M1-specific CD8+ T lymphocytes, and anti-
M1 T lymphocytes that were in contact with DC primed 
with the Dd-M1WW complex secreted IFN gamma, in-
dicating efficient capture, processing and presentation of  
the antigen by the dendritic cells.
To avoid problems with solubility of  the M1WW 
we applied an alternative approach, which involved the 
use of  specific epitopes derived from the M1 protein. 
We based our strategy on comprehensive ex vivo analy-
sis of  cross-reactive CD4+ and CD8+ memory T cell 
response to overlapping peptides spanning the full pro-
teome of  two influenza strains (Lee et al., 2008). This 
analysis showed that the key targets of  cross-recognition 
were M1 and nucleoprotein (NP). In addition, the ear-
lier investigation demonstrated that M1-derived peptides 
were able to recall memory CTL responses from human 
peripheral blood mononuclear cells (PBMC) (Gotch et 
al., 1987; Gianfrani et al., 2000; Plotnicky et al., 2003). 
For construction of  a vaccine that should induce hetero-
subtypic T cell-mediated immunity we engineered two 
immunodominant M1 epitopes FluM140–57 
— EALMEWLKTRPILSPLT(CD8+) and 
FluM155–72 —LTKGILGFVFTLTVPSER 
(CD4+ and CD8+) into the Dd structure. 
The epitopes have been inserted either in the 
variable loop of  Ad3 Pb or as an extension 
of  the Pb N-terminal domain without de-
stroying the particles’ dodecahedric structure 
(Fig. 2B). The final vaccine consisted of  a 
1:1 mixture of  two kinds of  Dd nanoparti-
cles, each bearing the M1 epitope in 60 cop-
ies.
Electron microscopy showed that insertion 
of  the FluM1 peptides into two different ex-
ternal sites of  Dd did not affect the vector 
assembly, as well as its entry potential; both 
DdFluM140–57 and DdFluM155–72 efficiently 
penetrated MDC, which was confirmed by 
confocal microscopy (Fig. 4B). In vitro as-
says demonstrated that our candidate vac-
cine exhibited no cytotoxic effect on human 
PBMC isolated from healthy donors. Impor-
tantly, FluM1 epitopes delivered on a Dd 
platform were efficiently captured by MDC, 
processed and presented by HLA class II 
and cross-presented by the HLA class I mol-
ecules, activating both CD8+ memory T cells 
and CD4+ T cells. In contrast, free FluM1 
peptides applied at concentrations exceeding 
those in Dd-FluM1 complex by about 20- 
fold showed no immunogenicity. These are 
important results, as an effective influenza 
vaccine should elicit specific CTLs that could 
provide protection against heterologous 
strains by targeting conserved viral proteins. 
Establishment of  memory T cells will not 
prevent the disease, but can promote viral 
clearance, reducing illness severity (Pushko et 
al., 2005).
Functionality of  the Dd-FluM1 vaccine 
was verified in chickens. For this, IFNγ secreted by im-
mune cells isolated from immunized chicken spleens was 
measured and ex vivo restimulated with the M1 peptides. 
It appeared that 50 µg of  DdFluM1 administered sub-
cutaneously acted as an efficient vaccine. High and con-
stant IFNγ level persisted until the 8th week after vac-
cination, suggesting strong and long lasting activation of  
T cells (Fig. 4C). Significantly, presence of  an adjuvant 
turned out to be dispensable, which suggests that the 
use of  adenoviral Dd as a vaccination platform might 
eliminate the necessity of  addition of  potentially harmful 
substances.
We wished to include in the vaccine a major influ-
enza antigen, hemagglutinin (HA), to provide a com-
plete defense against influenza infection. At first, we 
attempted to construct a vaccine with the HA protein 
attached externally to Dd through a previously de-
scribed adaptor containing WW domains (Naskalska et 
al., 2013). In the following approach the use of  the 
WW linker was abandoned as the linker alone (over 
100 amino acid residues) might elicit an immune re-
sponse. Instead, we decided to use a fragment of  
trimeric Ad3 fiber protein as a linker to Dd. As de-
scribed above, in the dodecahedra-fibers produced 
upon expression of  Ad3 pentons (complexes of  pen-
ton base and fiber, see Fig. 2A), the N-terminus of  a 
fiber nests in the cavity on the penton base surface 
(Cao et al., 2012), which results in formation of  the 
DF bearing 12 trimeric fibers. Therefore, hemaggluti-
Figure 3. Human myeloid dendritic cells (MDC) maturation upon Dd uptake.
(A) Optical microscopy images of MDC incubated with a buffer (negative con-
trol), Dd or lipopolysaccharide (LPS, positive control). (B) Expresssion of DC 
activation markers shown with flow cytometry after 48h culture of DC in the 
presence of Dd or M1WW alone, or with the Dd-M1WW complex and with li-
poteichoic acid (LTA, positive control). Maturation was observed by upregula-
tion of CD40 and CD80. After Naskalska et al. (2009).
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nin devoid of  TM, CT and SP was cloned in fusion 
with a fragment of  the fiber protein, which contained 
a region responsible for its attachment to the penton 
base prolonged by a fragment of  trimeric shaft, yield-
ing a fusion protein called Fi-HA. Sequences encoding 
Dd-FluM1 and Fi-HA were expressed simultaneously 
from one recombinant baculovirus. This approach re-
sulted in production of  soluble complexes containing 
Dd with attached Fi-HA. This material will be used in 
an influenza vaccine preparation and will be tested for 
its vaccination properties in the chicken model.
CONCLUSIONS
Virus-like particles are multimeric nanostructures as-
sembled from viral structural proteins responsible for 
cell penetration by the virus, ensuring efficient cell en-
try and thus tissue-specific targeting. It is important for 
vaccinology that VLPs present repetitive high-density 
displays of  epitopes and display excellent adjuvant prop-
erties capable of  inducing innate and cognate immune 
responses. VLPs provide delivery systems that combine 
good safety profiles with strong immunogenicity and 
Figure 4. Influenza vaccine constructed on a platform of adenoviral dodecahedron bearing epitopes derived from influenza M1 pro-
tein. 
(A) Left side — schematic view of constructs with M1 epitopes inserted into monomers of Ad3 penton base (Pb) protein that is a build-
ing block of Dd. Right side — diagram of vaccine formation. (B) Dd-M1 internalization into human dendritic cells, visualized by confocal 
microscopy using anti-Dd, anti-FluM140-57 and anti- FluM155-72 antibodies. Cell nuclei were counterstained with DAPI (blue signal). The 
last two columns show lack of internalization of free epitopes (ppt). (C) Chicken immunization with Dd-M1 vaccine. The graph shows 
secretion of IFN-γ (IFN gamma) by splenocytes of immunized or control chickens at the indicated time points (average values). One of 
three groups of chickens (n=25) was vaccinated with 50µg of the vaccine, while non-vaccinated birds and those immunized with Dd vec-
tor (50µg) served as controls. Isolated splenocytes were restimulated with the 1:1 mixture of M140-57 and M155-72 peptides and secretion 
of IFN-γ was measured by ELISA. After Szurgot et al. (2013).
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constitute a safe alternative to inactivated infectious vi-
ruses. They present both, high-density B-cell epitopes 
for antibody production and intracellular T-cell epitopes, 
thus inducing, respectively, potent humoral and cellular 
immune responses. Uptake of  VLPs by antigen-present-
ing cells leads to efficient immune responses resulting in 
keeping pathogenic microorganism infections under con-
trol.
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